Inhibition of focal adhesion kinase with her-2 targeted antibody pertuzumab (Omnitarg®, 2C4) in breast cancer cells
Küçük Resim Yok
Tarih
2008
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Gene Therapy Press
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Pertuzumab (Omnitarg (R), 2C4) is a recombinant humanized monoclonal antibody targeted to extracellular region of HER-2. Previous results proved the inhibitory effect of Pertuzumab on the survival of breast cancer cells via MAPK and AM pathway. Focal adhesion kinase (FAK) regulates multiple cellular processes including growth, differentiation, adhesion, motility and apoptosis. Here, we aimed to investigate the effects of Pertuzumab on ligand activated total FAK expression and phosphorylation in the HER-2 overexpressing BT-474 breast cancer cell line. Heregulin,vas used for ligand activation. We have found that FAK expression and phosphorylation were inhibited in with Pertuzumab in breast cancer cells.
Açıklama
Anahtar Kelimeler
Pertuzumab, Omnitarg (R), 2C4, focal adhesion kinase, breast cancer
Kaynak
Gene Therapy and Molecular Biology
WoS Q Değeri
Q4
Scopus Q Değeri
N/A
Cilt
12B
